Shigella vaccines are therapeutic agents used in preventing shigellosis infections caused by Shigella bacteria. Shigellosis often referred to as bacillary dysentery, causes abdominal cramps, fever, diarrhea containing mucus or blood in the stool. Development of effective shigella vaccines are crucial in preventing the spread of the disease especially in developing nations with poor sanitation and hygiene conditions.
The global Shigella Vaccines Market is estimated to be valued at US$ 574.20 mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of shigellosis infections globally particularly in developing countries is a major factor responsible for the growth of Shigella Vaccines Market. As per WHO, shigellosis is one of the major causes of moderate to severe diarrhea worldwide with about 80–165 million cases reported annually. Children under 5 years of age are the most affected and it is estimated that approximately 40,000 children die each year due to complications from shigellosis. Thus, prevalence of the disease has been catalyzing the demand for shigella vaccines to curb the spread of infection. Development of effective Shigella vaccines can help prevent a significant number of infections and deaths especially in developing nations where sanitation and hygiene levels remain poor.
SWOT Analysis
Strength: Shigella vaccines offer proactive prevention against Shigella infection caused by Shigella bacteria. They reduce the burden of antibiotic resistance due to overprescription of antibiotics to treat shigellosis.
Weakness: Development of Shigella vaccines is challenging due to the presence of multiple serotypes of S. dysenteriae and S. flexneri. Limited availability of second-generation vaccine candidates in clinical trials.
Opportunity: Rising incidence of Shigella infection globally especially in developing nations provides significant market potential. Increasing investments in research and development of improved vaccine candidates.
Threats: Stringent regulatory pathways for approval of new vaccines increases costs and timelines. Safety concerns regarding cross-protection between serotypes limits widespread adoption.
Key Takeaways
The global Shigella vaccines market is expected to witness high growth over the forecast period of 2023 to 2030.
Regionally, the market in Asia Pacific is expected to dominate due to increasing prevalence of shigellosis in densely populated countries. India accounts for the largest burden globally with maximum number of reported cases annually.
Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. These manufacturers are investing in the development of novel vaccines with improved efficacy and safety profiles. MSD Wellcome Trust Hilleman Laboratories’ oral live-attenuated tetravalent vaccine candidate is in phase 3 clinical trials.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
